Infants' immunisations, their timing and the risk of allergic diseases (INITIAL): an observational prospective cohort study protocol.


Journal

BMJ open
ISSN: 2044-6055
Titre abrégé: BMJ Open
Pays: England
ID NLM: 101552874

Informations de publication

Date de publication:
23 06 2023
Historique:
medline: 26 6 2023
pubmed: 25 6 2023
entrez: 24 6 2023
Statut: epublish

Résumé

Vaccinations are considered to have a large impact on disease control, hence a multitude of vaccines in infancy is recommended. Retrospective studies suggest a possible relation between timing, kind or number of vaccines given in the first year of life and the subsequent incidence of allergic diseases. It must be clarified whether a causal relationship exists to ensure safety and reduce vaccine hesitancy. Due to the high recommendation rate of vaccines, a long-term randomised controlled trial is not considered as ethically acceptable. Therefore, this study aims to observe prospectively the allergic incidence at the age of 5 years after various vaccine interventions in the early months of life.Parents of infants up to the age of 4-6 weeks will be recruited before the first recommended vaccination. Relevant prognostic factors for allergies, status of immunisation and general health will be evaluated up to the age of 5.Allergic symptoms will be assessed by the International Study of Asthma and Allergies in Childhood-questionnaire and a medical confirmation of the allergy is mandatory.The main objective is to compare the incidence of asthma, atopic dermatitis, rhinoconjunctivitis, food allergy or any of these atopies at the age of 5 between infants who were not vaccinated or were vaccinated according to recommendations in the first year of life.The sample size calculation with about 4000 participants can prove a 5% difference to the basic prevalence with about 80% power and global 5% alpha error for the five primary endpoints adjusting according to Bonferroni-Holm and assuming a rate of 10% not early vaccinated infants. The study was registered (DRKS00029677) and has received approval by the ethics committee of Universität Witten/Herdecke (no. 113/2022). The results will be published.

Identifiants

pubmed: 37355269
pii: bmjopen-2023-072722
doi: 10.1136/bmjopen-2023-072722
pmc: PMC10314580
doi:

Substances chimiques

Vaccines 0

Banques de données

DRKS
['DRKS00029677']

Types de publication

Clinical Trial Protocol Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e072722

Informations de copyright

© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: None declared.

Références

EClinicalMedicine. 2018 Nov 06;4-5:92-98
pubmed: 31193660
Cochrane Database Syst Rev. 2021 Nov 22;11:CD004407
pubmed: 34806766
MMWR Morb Mortal Wkly Rep. 2011 Jun 24;60(24):814-8
pubmed: 21697806
Allergy. 2014 Jan;69(1):62-75
pubmed: 24205824
Front Vet Sci. 2018 May 28;5:99
pubmed: 29892604
Allergy. 2021 Jul;76(7):2135-2152
pubmed: 33569761
BMJ Open. 2019 Sep 18;9(9):e029794
pubmed: 31537568
Pediatr Allergy Immunol. 2008 Feb;19(1):46-52
pubmed: 18086216
Eur Clin Respir J. 2015 Mar 24;2:
pubmed: 26557262
MMWR Morb Mortal Wkly Rep. 2014 Apr 25;63(16):352-5
pubmed: 24759657
Environ Health Prev Med. 2020 Jul 7;25(1):27
pubmed: 32635895
J Biomed Inform. 2019 Jul;95:103208
pubmed: 31078660
Pediatr Allergy Immunol. 2008 Sep;19(6):544-51
pubmed: 18266826
J Am Acad Dermatol. 2014 Feb;70(2):338-51
pubmed: 24290431
J Biomed Inform. 2009 Apr;42(2):377-81
pubmed: 18929686
Curr Opin Infect Dis. 2011 Jun;24(3):190-5
pubmed: 21415741
Pediatr Allergy Immunol. 2017 Nov;28(7):628-640
pubmed: 28779496
Lancet Infect Dis. 2016 May;16(5):592-598
pubmed: 26873665
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2007 May-Jun;50(5-6):578-89
pubmed: 17514442
Pediatr Allergy Immunol. 2012 Dec;23(8):737-46
pubmed: 23005697
SAGE Open Med. 2020 May 27;8:2050312120925344
pubmed: 32537156
Acta Derm Venereol. 2003;83(6):445-50
pubmed: 14690341
Vaccine. 2017 Sep 12;35(38):5156-5162
pubmed: 28801155
Pediatrics. 2003 Mar;111(3):e282-8
pubmed: 12612285
Br J Dermatol. 2021 Feb;184(2):304-309
pubmed: 33006135
Pediatr Allergy Immunol. 2015 Dec;26(8):742-9
pubmed: 25845848
Allergy. 2016 Apr;71(4):541-9
pubmed: 26707796
Vaccine. 2021 Mar 26;39(13):1805-1811
pubmed: 33648762
Biomed Res Int. 2019 Apr 21;2019:2450605
pubmed: 31119157
BMC Med Res Methodol. 2019 Dec 9;19(1):233
pubmed: 31818263

Auteurs

Jennifer Wrenger (J)

Faculty of Health/School of Medicine, Witten/Herdecke University, Witten, Germany.

David D Martin (DD)

Faculty of Health/School of Medicine, Witten/Herdecke University, Witten, Germany.
University Children's Hospital, Tübingen University, Tübingen, Germany.

Ekkehart Jenetzky (E)

Faculty of Health/School of Medicine, Witten/Herdecke University, Witten, Germany Ekkehart.Jenetzky@uni-wh.de.
Department for Child and Adolescent Psychiatry and Psychotherapy, Johannes Gutenberg University Mainz, Mainz, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH